The appetite for monetary easing in the region has been diminishing. The Serbian central bank kept the key rate steady at ...

March had been expected to be difficult due to a "combination of heavy supply, low redemptions, rate volatility, tax-related selling and now fund outflows," said Barclays strategists Mikhail Foux and ...

CytomX Therapeutics CTMX, a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on March 6, after market close. The company leverages its proprietary PROBODY ...

IndyCar will add a new street race in suburban Dallas next year, with the IndyCar Grand Prix of Arlington contested around ...

Oct 10, 2024 (Oct) 21:00 5.75% 5.75% ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...

Progress in the clinical development of CX-2051, targeted at advanced colorectal cancer, with initial Phase 1a clinical data expected in the first half of 2025. CytomX maintains a strong financial ...

UK-based wealth manager Brooks Macdonald Group has expanded its Scotland operations by hiring three investment professionals ...

A simple calendar can’t be a security risk, right? Wrong. If you buy something using links in our stories, we may earn a commission. This helps support our journalism. Learn more. Please also ...